ConductScience.org, home

Comparison · NCT01107743-c8f225fd

Without Complications vs With Complications: Risk Factors for the Proportion of Responders for Hypertension -Complications.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Without Complications vs With Complications: Risk Factors for the Proportion of Responders for Hypertension -Complications. Trial comparisons, record NCT01107743-c8f225fd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01107743-c8f225fd

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.950.9280.965wilson
Risk in group 20.9640.9470.976wilson
Risk difference, group 1 minus group 2-0.0149-0.03940.00815newcombe hybrid score
Risk ratio, group 1 over group 20.9850.9611.01log
Odds ratio, group 1 over group 20.6940.3951.22log
Number needed to treat, for one fewer participant with the outcome on Without Complications than on With Complications67.1from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Without ComplicationsParticipants without Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert.527555OG000
Group 2With ComplicationsParticipants with Complications who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert.624647OG001

Outcome

Type
SECONDARY
Title
Risk Factors for the Proportion of Responders for Hypertension -Complications.
Description
Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Complications is significant risk factor for Hypertension.
Time frame
8 weeks
Population
The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).

Source ClinicalTrials.gov

Trial

Title
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
NCT number
NCT01107743
Phases
Conditions
Hypertension, Angina Pectoris, Hypercholesterolemia, Familial Hypercholesterolemia
Interventions
Amlodipine/Atorvastatin
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Results first posted
2013-05-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01107743-c8f225fd